B-Cell Lymphoma Clinical Trials

Find B-Cell Lymphoma Clinical Trials Near You

Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma Across the Military Healthcare System

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin lymphoma among active-duty service members and other Military Health System beneficiaries. The main questions are whether specific exposures and germline variants are associated with B-cell NHL subtype, immune dysfunction, and clinical outcomes. Participants will complete exposure and medical-history surveys, provide biospecimens for immune and genomic testing, and may be followed annually for up to 3 years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 4
Healthy Volunteers: f
View:

• Age 4 years old and older with a clinical diagnosis of B-cell NHL.

• Must be willing to undergo phlebotomy and/or skin punch biopsy.

• Must be willing to undergo whole genome sequencing, which includes return of primary and secondary findings.

Locations
United States
Maryland
Uniformed Services University of the Health Sciences
ACTIVE_NOT_RECRUITING
Bethesda
Walter Reed National Military Medical Center
RECRUITING
Bethesda
Virginia
Naval Medical Center Portsmouth
ACTIVE_NOT_RECRUITING
Portsmouth
Contact Information
Primary
Christin B. Destefano, MD, Lt Col, MC, USAF
christin.destefano@usuhs.edu
(301) 295-3190
Backup
W. Grant Day, MD, LCDR, MC, USN
william.g.day26.mil@health.mil
(757) 953-2194
Time Frame
Start Date: 2025-05-01
Estimated Completion Date: 2028-05-01
Participants
Target number of participants: 300
Treatments
Cohort 1
Active duty service members (ADSMs) and other Military Health System (MHS) beneficiaries who have a history of B-cell non-Hodgkin Lymphoma (NHL) and have achieved clinical remission.
Cohort 2
ADSMs and other MHS beneficiaries ages 18 and older who are newly diagnosed with B-cell NHL and/or are not undergoing active treatment.
Cohort 3
Other MHS beneficiaries ages 4-17 who are diagnosed with B-cell NHL and are treatment naive.
Related Therapeutic Areas
Sponsors
Collaborators: The American Genome Center, United States Naval Medical Center, Portsmouth, Children's Hospital Medical Center, Cincinnati, Murtha Cancer Center, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center
Leads: Henry M. Jackson Foundation for the Advancement of Military Medicine

This content was sourced from clinicaltrials.gov

Similar Clinical Trials